Inrebic (fedrantinib)

pCPA File Number: 21527
Negotiation Status:
Under consideration for negotiation
Indication(s):
splenomegaly &/or disease-related symptoms in adult patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis, including patients previously exposed to ruxolitinib
Sponsor/Manufacturer:
Celgene Inc.
CADTH Project Number:
PC0205-000
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable